anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This study explores the association between obesity, diabetes, and somatosensory functioning in patients with knee osteoarthritis (OA), aiming to understand how metabolic conditions are related to pain mechanisms in this patient population. We hypothesized that higher body mass index (BMI), fat mass, and glycated hemoglobin levels (HbA1c) are associated with signs of altered somatosensory functioning.
METHODS: A cross-sectional analysis was conducted as part of a larger multicentre prospective cohort study. Data were collected from patients awaiting total knee arthroplasty in Belgium and the Netherlands. Associations between BMI, fat mass, HbA1c, and various pain-related variables were examined employing Pearson and Spearman correlation analyses which were further analyzed with linear regression techniques.
RESULTS: The study included 223 participants. Analysis revealed a significant although weak negative correlation between fat mass and pressure pain thresholds (PPT) at multiple locations, suggesting a link between higher fat mass and increased mechanical hyperalgesia. There were no significant correlations between BMI and pain-related outcomes. HbA1c levels showed very weak positive correlations with pain measures but did not withstand correction for multiple testing.
CONCLUSION: The findings indicate that fat mass may be closely associated with altered somatosensory functioning in patients with knee OA. However, no significant correlations were found between BMI or HbA1c levels and pain-related outcomes. Future research should focus on longitudinal studies to elucidate the causal relationships and further explore the impact of metabolic factors on pain mechanisms in this patient population. Key Points • The findings indicate that fat mass may be closely associated with altered somatosensory functioning in patients with knee OA.
Participants in the treatment group will be asked to meet with an occupational therapist in their home weekly over 12 weeks. Each session takes an hour. In the first session, the occupational therapist will introduce the program. In session 2, the therapist will discuss pain and pain management with the participant. In session 3-12, the therapist will help the participant to develop physical activity and healthy eating habits. In each session the participant will pick two healthy behaviors to turn them into a habit. The therapist will give the participant a workbook and teach the participant to track his/her progress. The focus of session 3-5 will be physical activity, and session 6-11 will be healthy eating. In the last session (session 12), the therapist will wrap up the program and help the participant to develop a maintenance plan.
Hormones are separated from crude aqueous liquids containing them, obtained from natural sources, by addition of a soluble ferro- or ferricyanide and a metal salt forming therewith an insoluble precipitate having adsorbent properties and then separating the hormone from the adsorbate by means of solvents. The liquids treated may be urine, serum, and extracts of the pituitary body, ovaries, corpora lutea, placentae or testicles. The soluble ferroor ferri-cyanides may be those of alkali metals, aluminium, barium or magnesium, and the metal salts may be cupric salts or zinc salts in the case of ferricyanides, and cobaltous, manganous and zinc salts in the case of ferrocyanides.  The suitability of any particular precipitate may be tested by ascertaining its power to absorb methylene blue form its solution.  The reaction is carried out at a pH value between 3 and 7, preferably at pH5.  According to examples a precipitate formed by reaction of zinc sulphate and potassium ferrocyanide is formed in (1) women's urine, the adsorbate being extracted with acetone to obtain oestrin and then with dilute ammonia to obtain gonadotropic hormone; (2) mares' urine, the adsorbate being extracted with acetone or alcohol to obtain oestrin; (3) mares' serum which has been pre-treated with picric acid to remove proteins; (4) an alkaline extract of anterior lobes of pituitary bodies which has been adjusted to pH 7,2 to separate a precipitate and then to pH 5,5 to cause precipitation of a mammae-stimulating hormone, the alkalisoluble anterior pituitary hormones being extracted from the adsorbate by dilute ammonia.
The invention discloses a Chinese traditional medicine decoction for external treating acne. The invention is characterized in that the medicine is prepared by the raw materials with the following parts by weight: Sulphur 10g, Realgar 10g, Camphora 3g, Cortex Phellodendri 20g, Radix Paeoniae Rubra 20g, Poria 30g and Radix Angelicae Dahuricae 15g. The medicine is decocted and applied externally, with one dose for one day and 2-3 times in a day. Almost 3000 ml water is added firstly into the drugs and boiled, residues are filtered out and the liquid is poured into a basin. The patient fumigates the focus first when the liquid is still hot and then washes the focus, with each time for 20 minutes. The description can remove the focus and the symptom of the acne, solving the temporary problem and can completely improve and strengthen blood circulation in veins, expelling the stasis and haemorrhoids, solving the permanent cure problem; therefore the invention solves both temporary solution and permanent cure and has evident effect.
In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
The proposed study is a pilot study designed to determine the efficacy and safety of serial ketamine infusions among veterans with treatment-resistant depression (TRD) as well as chronic post-traumatic stress disorder (PTSD). The investigators hypothesize that six infusions of ketamine will be effective in decreasing severity of depressive symptoms and maintaining response.

Participants will be male/female veterans (18 to 75 years old) of any era or military background who suffer from TRD and chronic PTSD. Potential participants will be recruited from Mental Health clinics and screened for eligibility using a two stage process (phone/chart review, followed by interview). Participants will receive six ketamine infusions on a Monday-Wednesday-Friday schedule over 2 weeks. On the day of infusion, participants will be required to stay at the clinical site for 3 hours after the medication has been given. Follow-up visits will occur at different time points over the course of 2 months after the two week infusion period has been completed.
Women are exceptionally vulnerable during childbearing years to gain disproportionally large amounts of weight when compared to men or other life periods. Weight gained during pregnancy and retained after the postpartum period contributes to obesity development and progression. Evidence based lifestyle interventions addressing the trajectory of weight gain across the childbearing continuum can reverse these alarming trends of excessive weight among young women, but have had limited uptake due to time, expense, and parenting priorities. To address this gap, our research team developed the lifestyle intervention Healthy Eating, Activity Living, Taught at Home during Pregnancy and Postpartum (HEALTH-P2) in partnership with Parents as Teachers (PAT). This study will provide evidence for the dissemination and implementation (D\&I) of HEALTH-P2 across PAT's network of sites, promoting healthy weight on a national scale. The study builds on our previous work with a pragmatic cluster randomized controlled trial to evaluate D\&I of HEALTH-P2 across multiple levels to achieve widespread impact. First, we will determine weight outcomes (12-month postpartum weight; gestational weigh gain) among 336 overweight/obese women (N=168 HEALTH-P2; N=168 usual care) when parent educators (\~8/site) from PAT sites nationwide receive the HEALTH-P2 training through PAT National Center's existing training infrastructure and conduct HEALTH-P2 as part of routine practice. From a D\&I perspective, an evaluation guided by RE-AIM will measure implementation outcomes (acceptability, appropriateness, feasibility, fidelity, adaptation). Further, the Conceptual Framework for Implementation Research will guide an assessment of contextual factors that influence external validity at multiple levels (mother, parent educator, PAT site).
PURPOSE: To provide a masticatable tablet by which the gustatory sensation of active components is concealed and desired biopotency is obtd. CONSTITUTION: The masticatable medicinal tablet is prepd. by subjecting a drug (e.g.; famotidine) to spin granulation together with a binder, for example, polyvinyl pyrrolidone and a carrier material, for example, lactose, to prepare spin granules, subjecting these spin granules to coating with a polymer mixture composed of cellulose acetate(CA) or/and cellulose acetate butyrate(CAB) and polyvinyl pyrrolidone(PVP) (the mixture composed of CA or/and CAB PVP=95:5 to 60:40, more preferably CA:PVPP=80:20), then compressing the granules together with an excipient. The spin granules preferably consist of 2 to 25 wt.% drug, 4 to 10 wt.% binder and 10 to 94 wt.% carrier material. The polymer mixture is preferably 5 to 20 wt.% of the total weight of the coating granulation flow. The examples of the drug to be coated includes loperamide, cimetidine and ranitidine.
This is a multicenter, open-label (identity of the assigned study treatments will be known to patients and study staff) study to determine the dose of the combination of trabectedin (Yondelis) and Doxorubicin for which the neutropenia (low white blood cell counts) is manageable with the use of filgrastim (an agent used to manage neutropenia) and associated with clinically acceptable number of side effects severe enough to continuation of treatment in patients with recurrent or persistent soft tissue sarcoma (STS, a malignant tumor that attacks the body's infrastructure of fat, muscles, nerves, joints, blood vessels, or deep skin tissues). Patients will be enrolled in the study after all study-specific entry criteria are met and informed consent is obtained. Patients will be required to attend regular clinic visits to receive study medication and have their status monitored. A detailed explanation can be provided by the study physician (Investigator) conducting this study. Doxorubicin (50 to 75 mg/m2) will be given as a 10-15 minute intravenous (i.v.) infusion on Day 1 via a central venous catheter which is a tube placed into a large vein. Trabectedin (0.9 to 1.3 mg/m2) will be given as a 3 hour i.v. infusion, immediately following the administration of doxorubicin. Dexamethasone 20 mg will be given within 1 hour before the start of each doxorubicin i.v. infusion and filgrastim will be administered according to manufacturer's instructions.
BACKGROUND: Posaconazole (PCZ) plays a crucial role in the prophylaxis and treatment of invasive fungal infections in hematologic malignancies. PCZ concentrations reportedly vary among patients receiving delayed-release tablets (DRT). However, the factors influencing these concentrations remain insufficiently elucidated. Therefore, this study aimed to evaluate the factors influencing PCZ concentrations and their effect on the probability of target attainment (PTA) using a population pharmacokinetic (PPK) approach. We also explored the relationship between PCZ exposure and hepatotoxicity.
METHODS: This retrospective study included adult patients with hematologic malignancies who received PCZ DRT. A PPK model was developed based on observational data for 130 concentrations in 28 patients. Simulation analyses were performed to assess the PTA at standard doses of 0.7 and 1.0 mg/L for prophylaxis and treatment, respectively. Estimated concentrations were used to evaluate the correlation between PCZ exposure and hepatotoxicity.
RESULTS: Significant factors influencing PCZ concentrations included body weight, serum total protein levels, and diarrhea. Diarrhea correlated with decreased PCZ concentrations resulting in up to 26% lower PTA compared with that without diarrhea. Moreover, PTA declined markedly as the total protein levels decreased from 6.6 g/dL to 4.4 g/dL. The incidence of hepatotoxicity was 17.4% (4/23); no significant relationship could be established between the PCZ concentrations and hepatotoxicity ( P = 0.188).
CONCLUSIONS: We identified the factors affecting PCZ exposure, which could not be detected by PPK analysis using data from clinical trials. Our results suggest that the generally recommended dose of PCZ causes underexposure in patients with hematologic malignancies characterized by high body weight, hypoproteinemia, or concurrent diarrhea. Therapeutic drug monitoring for DRT may be recommended, especially in patients with these risk factors.
Durvalumab in combination with tremelimumab and platinum-based doublet chemotherapy. Only subjects who achieve stable disease or better radiological response after 4 cycles of induction treatment will be eligible to continue study treatment with durvalumab in maintenance.
The invention discloses a double-functional nano-composite spheres based on metal ion-inducing polypeptide self-assembly and a preparation method thereof. In the invention, by means of a one-step reaction synthesis method, with [alpha]-lactalbumin hydrolyzed polypeptide as a carrier, the nano spheres are self-assembled under induction by Ca<2+> and Gd<3+> together, wherein the nano spheres, during self-assembly, are wrapped by a photosensitive agent, rose Bengal. The particle size of the nano-composite spheres can be adjusted and controlled in the range of 100-500 nm. The Gd<3+> which participates in the inductive sphere forming is used as a contrast medium unit of magnetic resonance imaging and the T1-weighted nuclear magnetic resonance signal response can be effectively increased so that the magnetic resonance imaging diagnosis to a tumor site can be performed. The rose Bengal wrapping the nano-composite spheres can release singlet oxygen to kill tumor cells under excitation illumination at 550 nm, thereby achieving the effect of photodynamic treatment. The nano-composite spheres are toxic-free without illumination. Meanwhile, the treatment process allows tracing through the magnetic resonance imaging. In addition, the nano-composite spheres are low in preparation cost, are simple in processes, and have a potential wide application prospect in the bio-medicinal field.
FIELD: medicine, pulmonology. SUBSTANCE: method involves the use of 5% solution of ε-aminocaproic acid as an antiedemic agent. Preparation is administrated by inhalation route, 2 times per 24 h (not rare) at the dose 5-10 ml per a seance. Method ensures to avoid the use of drug showing adverse effects (as ephedrine) and provides high effectiveness of treatment of patients with bronchial asthma, in part, due to topical using by specially developed schedule treatment. EFFECT: enhanced effectiveness of treatment. 3 ex
Ibuprofen is a widely used analgesic and antipyretic in adults and children. Two ibuprofen suppository formulations have been developed for pediatric use to facilitate dosing in younger age groups. This is a single-dose, balanced, randomised, three-period crossover study in healthy male and female adult volunteers. Each volunteer will receive a single dose of 50 mg ibuprofen as a suppository, a single dose of 200 mg ibuprofen as a suppository and a single oral dose of 200 mg ibuprofen (tablet). There will be 14 blood samples taken over 12 hours in each study period. Concentrations in plasma of ibuprofen and its S and R enantiomers will be measured using a validated chromatographic method. Standard pharmacokinetic parameters will be obtained and bioavailability on the basis of rate and extent of drug absorption will be assessed.
PROBLEM TO BE SOLVED: To provide water suitable for drinking.SOLUTION: To purify water to make drinking water having pH value near 7, namely near neutral water. By adjusting pH, health of human is retained. By using Lanvin D'arpege perfumery room colon, body condition is adjusted, common cold is cured, and number of eye cells is increased and the eyesight is increased. By using sugar contained in sugarcane, and alkaline natural water, human body does not require medicine. Men should use high resistance value water with pH value in a range of 7.13 to 7.87, women should use high resistance value water with pH value in a range of 7.12 to 7.89 to improve body condition, which helps person who could not stand stand by oneself. By using water with pH value of 7.4125, the number of brain cells is increased and dementia is cured. A boy is born from a woman with pH value of 7.25 to 7.48, and a girl with pH value of 7.42 to 7.77. A perfect child is born by gap of pH value by 0.2 for gap of pH value by 0.1. A girl is born from a man with pH value of 7.36 to 7.43 and a woman with pH value of 7.44 to 7.77. A perfect girl is born by gap of pH value by 0.3 for gap of pH value by 0.1.
PURPOSE: The purpose of this study was to describe lung abnormalities observed on computed tomography (CT) in patients meeting the 2016 American College of Rheumatology/European League Against Rheumatism (EULAR) classification criteria for primary Sjögren's disease (pSD).
MATERIALS AND METHODS: All patients with pSD seen between January 2009 and December 2020 in the day care centre of our National Reference Center for rare systemic autoimmune diseases, who had at least one chest CT examination available for review and for whom the cumulative EULAR Sjögren's Syndrome Disease Activity Index (cumESSDAI) could be calculated were retrospectively evaluated. CT examinations were reviewed, together with clinical symptoms and pulmonary functional results.
RESULTS: Seventy-seven patients (73 women, four men) with a median age of 51 years at pSD diagnosis (age range: 17-79 years), a median follow-up time of 6 years and a median cumESSDAI of 7 were included. Sixty-six patients (86%) had anti-SSA antibodies. Thirty-three patients (33/77; 43%) had respiratory symptoms, without significant alteration in pulmonary function tests. Forty patients (40/77; 52%) had abnormal lung CT findings of whom almost half of them had no respiratory symptoms. Abnormalities on chest CT were more frequently observed in patients with anti-SSA positivity and a history of lymphoma. Air cysts (28/77; 36%) and mosaic perfusion (35/77; 35%) were the predominant abnormalities, whereas lung fibrosis was observed in five patients (5/77; 6%).
CONCLUSION: More than half of patients with pSD have abnormal CT findings, mainly air cysts and mosaic perfusion, indicative of small airways disease, whereas lung fibrosis is rare, observed in less than 10% of such patients.
This intervention entails the intake of white bread which provides 64.3 g (50 g + 14.3 g) of carbohydrates and water. This intervention would be the comparator in carbohydrates-equally conditions.
Participants with diagnosis of moderate to severe Crohn's disease (CD) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and CD at Day 1 were followed up for 12 months in prospective phase.
This study will assess the toxicity/safety of CHOP chemotherapy given concurrently with rituximab, followed by maintenance PEG Intron in patients with anthracycline naïve indolent non-Hodgkin's lymphoma. This study will also evaluate response rates, time to progression, molecular response, and immunologic parameters related to this treatment. Adult patients with indolent, advanced stage, anthracycline naive NHL requiring treatment may be eligible. Patients must have measurable disease, no severe organ dysfunction, and normal ejection fraction in older patients. Patients also must have adequate hematologic, hepatic and renal function, performance status, and life expectancy of at least 18 months. Patients may not have CNS lymphoma, uncontrolled co-morbid conditions, pregnancy, HIV, and active psychiatric conditions. Additionally, patients may not have had prior hypersensitivity to interferon-alpha, other cancer within 5 years, significant heart disease or myocardial infarction within the last 6 months, and history of thrombosis. Additionally, patients will have an ocular exam prior to treatment.

Patients in this study will receive 6 cycles of combination chemotherapy with the standard CHOP regimen given in conjunction with rituximab. Cycles are repeated at 21-day intervals for six to eight cycles. Patients achieving at least a partial response to chemotherapy will begin PEG Intron at a dose of 2g/kg/week subcutaneously. PEG Intron treatment will be continued for 12 months in the absence of signs of progressive/recurrent disease, or unacceptable toxicity/intolerance of therapy. PEG Intron dosing will be adjusted based on the presence of symptoms or other clinical manifestations of toxicity. Patients will undergo bone marrow evaluation for molecular testing at baseline. Those found to be positive will have repeat assessments performed post induction therapy, and after six months of PEG Intron. Patients will also undergo immunologic evaluation at baseline, post induction therapy, and after six months of PEG Intron. At the end of PEG Intron therapy, patients will have disease reevaluation and then annual data collection for long-term toxicity, duration of response and survival.
The invention discloses a TCR capable of specifically recognizing HLA-A 02:01/WT1 targets and application thereof. The CDR1, CDR2 and CDR3 of the alpha chain variable region of the TCR respectively comprise sequences shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 or respectively comprise variants of the sequences shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO. 3; the variant has 4, 3 or less than 2 mutations compared to the pre-mutated sequence, and the variant retains at least the function of the pre-mutated sequence. The TCR of the invention has high affinity with HLA-A 02:01/RMFPNAPYL target, K  D  The (M) value may even be up to 1.7. Mu.M. And these mutant transduced T cells activate specifically to target cells.
One of the distinctive pathological features of Alzheimer's disease (AD) is the deposition of amyloid plaques within the brain of affected individuals. These plaques have traditionally been investigated using labeling techniques such as immunohistochemical imaging. However, the use of labeling can disrupt the structural integrity of the molecules being analyzed. Hence, it is imperative to employ label-free imaging methods for noninvasive examination of amyloid deposits in their native form, thereby providing more relevant information pertaining to AD. This study presents compelling evidence that label-free and nondestructive confocal Raman imaging is a highly effective approach for the identification and chemical characterization of amyloid plaques within cortical regions of an arcAβ mouse model of AD. Furthermore, this investigation elucidates how the spatial correlation of Raman signals can be exploited to identify robust Raman marker bands and discern proteins and lipids from amyloid plaques. Finally, this study uncovers the existence of distinct types of amyloid plaques in the arcAβ mouse brain, exhibiting significant disparities in terms of not only shape and size but also molecular composition.